



[Koneksa](#) is a patient-centric digital biomarker company that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

V3 framework was transformational for educating the scientific community, making it receptive to the ideas of how to validate biometric monitoring technologies for use in clinical trials.

— **Elena Izmailova, PhD,**
Chief Scientific Officer, Koneksa



The Opportunity

- » Researchers from Koneksa sought to demonstrate the **utility of digital measures of motor function in Parkinson's disease.**



The Resource

- » Koneksa's work is fully aligned with the [V3 framework](#) exemplifying a systematic, stepwise evaluation of body worn sensors with data processing algorithm prior to testing in patients.
- » The study details: (1) the **technical verification** of accelerometers in an Apple iPhone 8 Plus and ActiGraph GT9X versus an oscillating table and (2) **analytical validation** software tasks for walking and pronation/supination on the iPhone plus passively detect walking measures with the ActiGraph in healthy volunteers versus human raters.



The Impact

- » **Using V3**, the researchers determined that the devices, sensors, software, and algorithms are sufficiently **fit-for-purpose to proceed** with the examination of usability and clinical validity in patients with Parkinson's disease.
- » The study also highlights the importance of detailing the technical verification and analytical validation steps in V3, in addition to clinical validation, the step most frequently detailed in peer review literature.

[Read the full study here](#)